VRCA
Verrica Pharmaceuticals Inc.
Biotechnology
Market Cap$142M
5Y Perf.-92.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
VRCA vs DERM vs PRGO vs NVCR vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$102M
5Y Perf.-36.8%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-68.1%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-82.0%
SKIN
The Beauty Health Company
Household & Personal Products
Market Cap$118M
5Y Perf.-96.5%
VRCA vs DERM vs PRGO vs NVCR vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VRCA | DERM | PRGO | NVCR | SKIN |
|---|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Household & Personal Products |
| Market Cap | $142M | $102M | $1.61B | $1.92B | $118M |
| Revenue (TTM) | $36M | $56M | $4.18B | $674M | $296M |
| Net Income (TTM) | $-18M | $-9M | $-1.82B | $-173M | $-6M |
| Gross Margin | 93.8% | 67.5% | 34.2% | 75.2% | 64.9% |
| Operating Margin | -34.2% | -12.2% | -4.1% | -27.2% | -3.6% |
| Forward P/E | — | 69.0x | 5.6x | — | — |
| Total Debt | $2M | $26M | $3.97B | $290M | $379M |
| Cash & Equiv. | $30M | $20M | $532M | $103M | $233M |
VRCA vs DERM vs PRGO vs NVCR vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VRCA
DERM
PRGO
NVCR
SKIN
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Verrica Pharmaceuti… (VRCA) | 100 | 8.0 | -92.0% |
| Journey Medical Cor… (DERM) | 100 | 63.2 | -36.8% |
| Perrigo Company plc (PRGO) | 100 | 31.9 | -68.1% |
| NovoCure Limited (NVCR) | 100 | 18.0 | -82.0% |
| The Beauty Health C… (SKIN) | 100 | 3.5 | -96.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VRCA vs DERM vs PRGO vs NVCR vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRGO leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Verrica Pharmaceuticals Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. SKIN also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
VRCA
Verrica Pharmaceuticals Inc.
The Growth Play
VRCA is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 370.2%, EPS growth 88.6%, 3Y rev CAGR 57.9%
- 370.2% revenue growth vs DERM's -29.1%
- +101.5% vs PRGO's -51.2%
Best for: growth exposure
DERM
Journey Medical Corporation
The Long-Run Compounder
DERM is the clearest fit if your priority is long-term compounding.
- -47.4% 10Y total return vs NVCR's 30.3%
Best for: long-term compounding
PRGO
Perrigo Company plc
The Income Pick
PRGO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower volatility, beta 1.18, current ratio 2.76x
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Better valuation composite
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Healthcare Pick
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
SKIN
The Beauty Health Company
The Quality Compounder
SKIN ranks third and is worth considering specifically for quality and efficiency.
- -2.0% margin vs VRCA's -50.3%
- -1.2% ROA vs VRCA's -42.3%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VRCA | 370.2% revenue growth vs DERM's -29.1% |
| Value | PRGO | Better valuation composite |
| Quality / Margins | SKIN | -2.0% margin vs VRCA's -50.3% |
| Stability / Safety | PRGO | Beta 1.18 vs NVCR's 2.20 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend |
| Momentum (1Y) | VRCA | +101.5% vs PRGO's -51.2% |
| Efficiency (ROA) | SKIN | -1.2% ROA vs VRCA's -42.3% |
VRCA vs DERM vs PRGO vs NVCR vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
FY 2025
Segment breakdown not available.
FY 2025
VRCA vs DERM vs PRGO vs NVCR vs SKIN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDERMLAGGINGNVCR
Who Leads Where
PRGO leads in 1 of 6 categories
SKIN leads 1 • DERM leads 1 • VRCA leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓NVCRNovoCure Limited
0leads
VRCAVerrica Pharmaceutica…
0leads
SKINThe Beauty Health Com…
1leads
PRGOPerrigo Company plc
1leads
DERMJourney Medical Corpo…
1leads
6 Total Categories
CATEGORYLEADERvs PRGOvs SKINMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PRGO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SKIN4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
DERM3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — VRCA and SKIN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 117.4x VRCA's $36M. SKIN is the more profitable business, keeping -2.0% of every revenue dollar as net income compared to VRCA's -50.3%. On growth, VRCA holds the edge at +13.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $36M | $56M | $4.2B | $674M | $296M |
| EBITDAEarnings before interest/tax | -$11M | -$3M | $58M | -$165M | $9M |
| Net IncomeAfter-tax profit | -$18M | -$9M | -$1.8B | -$173M | -$6M |
| Free Cash FlowCash after capex | -$18M | -$3M | $108M | -$48M | $29M |
| Gross MarginGross profit ÷ Revenue | +93.8% | +67.5% | +34.2% | +75.2% | +64.9% |
| Operating MarginEBIT ÷ Revenue | -34.2% | -12.2% | -4.1% | -27.2% | -3.6% |
| Net MarginNet income ÷ Revenue | -50.3% | -15.5% | -43.5% | -25.7% | -2.0% |
| FCF MarginFCF ÷ Revenue | -49.5% | -4.8% | +2.6% | -7.1% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.8% | +1.0% | -7.2% | +12.3% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +73.4% | +5.9% | -56.4% | -100.0% | +38.0% |
Evenly matched — VRCA and SKIN each lead in 3 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Market CapShares × price | $142M | $102M | $1.6B | $1.9B | $118M |
| Enterprise ValueMkt cap + debt − cash | $113M | $108M | $5.1B | $2.1B | $264M |
| Trailing P/EPrice ÷ TTM EPS | -4.90x | -6.94x | -1.14x | -13.80x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 68.97x | 5.56x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 7.42x | — | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 3.98x | 1.82x | 0.38x | 2.92x | 0.39x |
| Price / BookPrice ÷ Book value/share | 3.55x | 5.09x | 0.55x | 5.51x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 11.12x | — | 3.17x |
PRGO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
SKIN leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
SKIN delivers a -9.4% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-2 for VRCA. VRCA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs DERM's 2/9, reflecting strong financial health.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -45.4% | -50.7% | -50.8% | -9.4% |
| ROA (TTM)Return on assets | -42.3% | -10.8% | -19.8% | -16.5% | -1.2% |
| ROICReturn on invested capital | — | -56.8% | +3.7% | -16.4% | -6.8% |
| ROCEReturn on capital employed | -42.8% | -34.2% | +4.3% | -28.9% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 4 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.07x | 1.28x | 1.35x | 0.85x | 6.20x |
| Net DebtTotal debt minus cash | -$29M | $5M | $3.4B | $187M | $146M |
| Cash & Equiv.Liquid assets | $30M | $20M | $532M | $103M | $233M |
| Total DebtShort + long-term debt | $2M | $26M | $4.0B | $290M | $379M |
| Interest CoverageEBIT ÷ Interest expense | -1.33x | -1.52x | -7.20x | -96.80x | 0.81x |
SKIN leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
DERM leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DERM five years ago would be worth $5,263 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, VRCA leads with a +101.5% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors DERM at 44.7% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -0.7% | -32.9% | -13.5% | +28.3% | -35.0% |
| 1-Year ReturnPast 12 months | +101.5% | -28.1% | -51.2% | +1.1% | -35.9% |
| 3-Year ReturnCumulative with dividends | -87.6% | +203.0% | -58.1% | -75.7% | -91.7% |
| 5-Year ReturnCumulative with dividends | -92.8% | -47.4% | -60.1% | -91.3% | -92.9% |
| 10-Year ReturnCumulative with dividends | -95.3% | -47.4% | -77.7% | +30.3% | -91.6% |
| CAGR (3Y)Annualised 3-year return | -50.1% | +44.7% | -25.2% | -37.6% | -56.4% |
DERM leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VRCA and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRCA currently trades 83.9% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.19x | 1.82x | 1.18x | 2.20x | 2.00x |
| 52-Week HighHighest price in past year | $9.82 | $9.55 | $28.44 | $20.06 | $2.69 |
| 52-Week LowLowest price in past year | $3.28 | $4.31 | $9.23 | $9.82 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +83.9% | +52.3% | +41.2% | +83.9% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 75.4 | 44.3 | 60.9 | 69.8 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 110K | 230K | 3.4M | 1.5M | 760K |
Evenly matched — VRCA and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VRCA as "Buy", DERM as "Buy", PRGO as "Hold", NVCR as "Buy", SKIN as "Hold". Consensus price targets imply 135.0% upside for DERM (target: $12) vs 42.9% for SKIN (target: $1). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | VRCAVerrica Pharmaceu… | DERMJourney Medical C… | PRGOPerrigo Company p… | NVCRNovoCure Limited | SKINThe Beauty Health… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $17.00 | $11.75 | $20.00 | $33.50 | $1.30 |
| # AnalystsCovering analysts | 10 | 3 | 36 | 15 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — | — |
| Dividend StreakConsecutive years of raises | — | — | 10 | — | — |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRGO leads in 1 of 6 categories (Valuation Metrics). SKIN leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallJourney Medical Corporation (DERM)Leads 1 of 6 categories
Loading custom metrics...
VRCA vs DERM vs PRGO vs NVCR vs SKIN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is VRCA or DERM or PRGO or NVCR or SKIN a better buy right now?
For growth investors, Verrica Pharmaceuticals Inc.
(VRCA) is the stronger pick with 370. 2% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Verrica Pharmaceuticals Inc. (VRCA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VRCA or DERM or PRGO or NVCR or SKIN?
Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.
4%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus VRCA's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VRCA or DERM or PRGO or NVCR or SKIN?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 87% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Verrica Pharmaceuticals Inc. (VRCA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — VRCA or DERM or PRGO or NVCR or SKIN?
By revenue growth (latest reported year), Verrica Pharmaceuticals Inc.
(VRCA) is pulling ahead at 370. 2% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Verrica Pharmaceuticals Inc. grew EPS 88. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VRCA leads at 57. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VRCA or DERM or PRGO or NVCR or SKIN?
The Beauty Health Company (SKIN) is the more profitable company, earning -3.
2% net margin versus -50. 3% for Verrica Pharmaceuticals Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -33. 6% for VRCA. At the gross margin level — before operating expenses — VRCA leads at 93. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is VRCA or DERM or PRGO or NVCR or SKIN more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 69. 0x for Journey Medical Corporation — 63. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.
07Which pays a better dividend — VRCA or DERM or PRGO or NVCR or SKIN?
In this comparison, PRGO (9.
8% yield) pays a dividend. VRCA, DERM, NVCR, SKIN do not pay a meaningful dividend and should not be held primarily for income.
08Is VRCA or DERM or PRGO or NVCR or SKIN better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Verrica Pharmaceuticals Inc. (VRCA) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, VRCA: -95. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between VRCA and DERM and PRGO and NVCR and SKIN?
These companies operate in different sectors (VRCA (Healthcare) and DERM (Healthcare) and PRGO (Healthcare) and NVCR (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: VRCA is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; NVCR is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock. PRGO pays a dividend while VRCA, DERM, NVCR, SKIN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(VRCA: 1380.2% · DERM: 1.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.